Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis

Sorafenib, a multi-kinase inhibitor, has been reported to be associated with hypertension (HTN). However, the risk of severe HTN with sorafenib treatment has not been well described. We performed an up-to-date meta-analysis of high-grade HTN in cancer patients treated with sorafenib. Medline databas...

Full description

Saved in:
Bibliographic Details
Published inJournal of human hypertension Vol. 27; no. 10; pp. 601 - 611
Main Authors Funakoshi, T, Latif, A, Galsky, M D
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.10.2013
Nature Publishing Group
Subjects
692/699/67
692/699/75/243
692/700/565/1436
692/700/565/2194
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Blood Pressure - drug effects
Cancer
Cancer patients
Chemotherapy
Chi-Square Distribution
Clinical trials
Drug Administration Schedule
Enzyme inhibitors
Epidemiology
Health Administration
Health aspects
Humans
Hypertension
Hypertension - chemically induced
Hypertension - diagnosis
Hypertension - epidemiology
Hypertension - physiopathology
Immunotherapy
Incidence
Inhibitor drugs
Kidney cancer
Medicine & Public Health
Meta-analysis
Molecular Targeted Therapy - adverse effects
Neoplasms - drug therapy
Neoplasms - enzymology
Niacinamide - administration & dosage
Niacinamide - adverse effects
Niacinamide - analogs & derivatives
Odds Ratio
original-article
Patients
Phenylurea Compounds - administration & dosage
Phenylurea Compounds - adverse effects
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Public Health
Renal cell carcinoma
Risk Factors
Severity of Illness Index
Sorafenib
Targeted cancer therapy
Terminology
Time Factors
meta-analysis
cancer
sorafenib
hypertension
Online AccessGet full text

Cover

Abstract Sorafenib, a multi-kinase inhibitor, has been reported to be associated with hypertension (HTN). However, the risk of severe HTN with sorafenib treatment has not been well described. We performed an up-to-date meta-analysis of high-grade HTN in cancer patients treated with sorafenib. Medline databases and the American Society of Clinical Oncology online database of meeting abstracts were searched up to August 2012 for relevant clinical trials. Eligible studies included phase II and III trials of sorafenib in patients with any type of cancer describing events of HTN according to the Common Terminology Criteria for Adverse Events. The summary incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated. The incidence of sorafenib-associated high-grade (grade 3–4) HTN was 6.0% (95% CI 4.7–7.3) in a total of 4722 patients from 55 trials of sorafenib as a single agent. Sorafenib-treated patients (4878 subjects from 13 randomized trials) had a significantly higher risk of high-grade HTN (RR 3.20 (95% CI 2.19–4.68)). Subgroup analysis revealed a significantly higher RR of high-grade HTN in patients receiving sorafenib as a single agent compared with patients receiving concomitant chemotherapy or immunotherapy ( P =0.0076). The incidence of high-grade HTN associated with sorafenib was significantly higher in patients with renal cell carcinoma (RCC) than those with non-RCC cancer ( P <0.0001) as well as patients treated with sorafenib for a longer duration than those treated for a shorter duration ( P =0.003). The use of sorafenib is associated with a significantly higher risk of high-grade HTN compared with control.
AbstractList Sorafenib, a multi-kinase inhibitor, has been reported to be associated with hypertension (HTN). However, the risk of severe HTN with sorafenib treatment has not been well described. We performed an up-to-date meta-analysis of high-grade HTN in cancer patients treated with sorafenib. Medline databases and the American Society of Clinical Oncology online database of meeting abstracts were searched up to August 2012 for relevant clinical trials. Eligible studies included phase II and III trials of sorafenib in patients with any type of cancer describing events of HTN according to the Common Terminology Criteria for Adverse Events. The summary incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated. The incidence of sorafenib-associated high-grade (grade 3-4) HTN was 6.0% (95% CI 4.7-7.3) in a total of 4722 patients from 55 trials of sorafenib as a single agent. Sorafenib-treated patients (4878 subjects from 13 randomized trials) had a significantly higher risk of high-grade HTN (RR 3.20 (95% CI 2.19-4.68)). Subgroup analysis revealed a significantly higher RR of high-grade HTN in patients receiving sorafenib as a single agent compared with patients receiving concomitant chemotherapy or immunotherapy (P=0.0076). The incidence of high-grade HTN associated with sorafenib was significantly higher in patients with renal cell carcinoma (RCC) than those with non-RCC cancer (P<0.0001) as well as patients treated with sorafenib for a longer duration than those treated for a shorter duration (P=0.003). The use of sorafenib is associated with a significantly higher risk of high-grade HTN compared with control.Sorafenib, a multi-kinase inhibitor, has been reported to be associated with hypertension (HTN). However, the risk of severe HTN with sorafenib treatment has not been well described. We performed an up-to-date meta-analysis of high-grade HTN in cancer patients treated with sorafenib. Medline databases and the American Society of Clinical Oncology online database of meeting abstracts were searched up to August 2012 for relevant clinical trials. Eligible studies included phase II and III trials of sorafenib in patients with any type of cancer describing events of HTN according to the Common Terminology Criteria for Adverse Events. The summary incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated. The incidence of sorafenib-associated high-grade (grade 3-4) HTN was 6.0% (95% CI 4.7-7.3) in a total of 4722 patients from 55 trials of sorafenib as a single agent. Sorafenib-treated patients (4878 subjects from 13 randomized trials) had a significantly higher risk of high-grade HTN (RR 3.20 (95% CI 2.19-4.68)). Subgroup analysis revealed a significantly higher RR of high-grade HTN in patients receiving sorafenib as a single agent compared with patients receiving concomitant chemotherapy or immunotherapy (P=0.0076). The incidence of high-grade HTN associated with sorafenib was significantly higher in patients with renal cell carcinoma (RCC) than those with non-RCC cancer (P<0.0001) as well as patients treated with sorafenib for a longer duration than those treated for a shorter duration (P=0.003). The use of sorafenib is associated with a significantly higher risk of high-grade HTN compared with control.
Sorafenib, a multi-kinase inhibitor, has been reported to be associated with hypertension (HTN). However, the risk of severe HTN with sorafenib treatment has not been well described. We performed an up-to-date meta-analysis of high-grade HTN in cancer patients treated with sorafenib. Medline databases and the American Society of Clinical Oncology online database of meeting abstracts were searched up to August 2012 for relevant clinical trials. Eligible studies included phase II and III trials of sorafenib in patients with any type of cancer describing events of HTN according to the Common Terminology Criteria for Adverse Events. The summary incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated. The incidence of sorafenib-associated high-grade (grade 3-4) HTN was 6.0% (95% CI 4.7-7.3) in a total of 4722 patients from 55 trials of sorafenib as a single agent. Sorafenib-treated patients (4878 subjects from 13 randomized trials) had a significantly higher risk of high-grade HTN (RR 3.20 (95% CI 2.19-4.68)). Subgroup analysis revealed a significantly higher RR of high-grade HTN in patients receiving sorafenib as a single agent compared with patients receiving concomitant chemotherapy or immunotherapy (P = 0.0076). The incidence of high-grade HTN associated with sorafenib was significantly higher in patients with renal cell carcinoma (RCC) than those with non-RCC cancer (P<0.0001) as well as patients treated with sorafenib for a longer duration than those treated for a shorter duration (P = 0.003). The use of sorafenib is associated with a significantly higher risk of high-grade HTN compared with control. Journal of Human Hypertension (2013) 27, 601-611; doi: 10.1038/jhh.2013.30; published online 2 May 2013 Keywords: sorafenib; cancer; meta-analysis; hypertension
Sorafenib, a multi-kinase inhibitor, has been reported to be associated with hypertension (HTN). However, the risk of severe HTN with sorafenib treatment has not been well described. We performed an up-to-date meta-analysis of high-grade HTN in cancer patients treated with sorafenib. Medline databases and the American Society of Clinical Oncology online database of meeting abstracts were searched up to August 2012 for relevant clinical trials. Eligible studies included phase II and III trials of sorafenib in patients with any type of cancer describing events of HTN according to the Common Terminology Criteria for Adverse Events. The summary incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated. The incidence of sorafenib-associated high-grade (grade 3-4) HTN was 6.0% (95% CI 4.7-7.3) in a total of 4722 patients from 55 trials of sorafenib as a single agent. Sorafenib-treated patients (4878 subjects from 13 randomized trials) had a significantly higher risk of high-grade HTN (RR 3.20 (95% CI 2.19-4.68)). Subgroup analysis revealed a significantly higher RR of high-grade HTN in patients receiving sorafenib as a single agent compared with patients receiving concomitant chemotherapy or immunotherapy (P=0.0076). The incidence of high-grade HTN associated with sorafenib was significantly higher in patients with renal cell carcinoma (RCC) than those with non-RCC cancer (P<0.0001) as well as patients treated with sorafenib for a longer duration than those treated for a shorter duration (P=0.003). The use of sorafenib is associated with a significantly higher risk of high-grade HTN compared with control.
Sorafenib, a multi-kinase inhibitor, has been reported to be associated with hypertension (HTN). However, the risk of severe HTN with sorafenib treatment has not been well described. We performed an up-to-date meta-analysis of high-grade HTN in cancer patients treated with sorafenib. Medline databases and the American Society of Clinical Oncology online database of meeting abstracts were searched up to August 2012 for relevant clinical trials. Eligible studies included phase II and III trials of sorafenib in patients with any type of cancer describing events of HTN according to the Common Terminology Criteria for Adverse Events. The summary incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated. The incidence of sorafenib-associated high-grade (grade 3–4) HTN was 6.0% (95% CI 4.7–7.3) in a total of 4722 patients from 55 trials of sorafenib as a single agent. Sorafenib-treated patients (4878 subjects from 13 randomized trials) had a significantly higher risk of high-grade HTN (RR 3.20 (95% CI 2.19–4.68)). Subgroup analysis revealed a significantly higher RR of high-grade HTN in patients receiving sorafenib as a single agent compared with patients receiving concomitant chemotherapy or immunotherapy ( P =0.0076). The incidence of high-grade HTN associated with sorafenib was significantly higher in patients with renal cell carcinoma (RCC) than those with non-RCC cancer ( P <0.0001) as well as patients treated with sorafenib for a longer duration than those treated for a shorter duration ( P =0.003). The use of sorafenib is associated with a significantly higher risk of high-grade HTN compared with control.
Audience Academic
Author Funakoshi, T
Galsky, M D
Latif, A
Author_xml – sequence: 1
  givenname: T
  surname: Funakoshi
  fullname: Funakoshi, T
  email: tfunakoshi@chpnet.org
  organization: Department of Internal Medicine, Beth Israel Medical Center, University Hospital and Manhattan Campus for the Albert Einstein College of Medicine
– sequence: 2
  givenname: A
  surname: Latif
  fullname: Latif, A
  organization: Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine
– sequence: 3
  givenname: M D
  surname: Galsky
  fullname: Galsky, M D
  organization: Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23636006$$D View this record in MEDLINE/PubMed
BookMark eNp9kttrFTEQxoNU7EWffJeAIILuMbfdzfatFG9QEESfw2x2tpvjbvaYZC3nvzfHU7UtVQIJzPy-b4bMHJMDP3sk5ClnK86kfrMehpVgXK4ke0COuKqroixFfUCOWFOyohGKHZLjGNeM7ZL6ETkUspIVY9UR8Z9d_Ebnng7bDYaEPrrZU-epBW8x0A0khz5FmgJCwo5euTTQOAfo0bv2lIKny6b7lYrbmHDKAksD_nB4lZMdnTBBAR7GbXTxMXnYwxjxyfV7Qr6-e_vl_ENx8en9x_Ozi8IqzVLBRSVKaW0vlNbAbN1LCS2ovu-4aBVXfdc0rAEBSvMGyqouoVWoW2tlCfk6IS_3vpswf18wJjO5aHEcweO8RMOVFKxWpZYZfX4HXc9LyP1GIyrFqlI3XP-Pyl5cNmVZ13-pSxjRON_PKYDdlTZnUlUZ002VqdU9VD4dTs7m4fYux28JXtwQDAhjGuI8LinPKt4Gn113ubQTdmYT3ARha37POwOv9oANc4wB-z8IZ2a3TSZvk9ltk5Es0_wObV2CXdXcsBv_oXm918Ts7C8x3Pioe_Cf10TZGQ
CitedBy_id crossref_primary_10_3322_caac_21341
crossref_primary_10_1016_j_ctrv_2018_06_019
crossref_primary_10_1097_MD_0000000000003752
crossref_primary_10_1080_14740338_2023_2251398
crossref_primary_10_4254_wjh_v7_i20_2245
crossref_primary_10_1016_j_jaccao_2019_08_012
crossref_primary_10_1093_eurheartj_ehw211
crossref_primary_10_1007_s12672_022_00468_3
crossref_primary_10_2217_fon_14_136
crossref_primary_10_1021_acsomega_9b01699
crossref_primary_10_18632_oncotarget_25024
crossref_primary_10_1002_cncr_28972
crossref_primary_10_1097_FPC_0000000000000279
crossref_primary_10_3389_fmed_2023_1095344
crossref_primary_10_1007_s10147_014_0691_5
crossref_primary_10_1080_14740338_2018_1513489
crossref_primary_10_1093_ajh_hpy087
crossref_primary_10_1097_MJT_0000000000000331
crossref_primary_10_1016_j_jacc_2015_07_025
crossref_primary_10_1186_s13054_017_1678_1
crossref_primary_10_1002_ejhf_654
crossref_primary_10_1038_nrneph_2015_15
crossref_primary_10_1111_jch_12266
crossref_primary_10_18632_oncotarget_5853
crossref_primary_10_1186_s40959_020_00064_w
crossref_primary_10_1093_cvr_cvz022
crossref_primary_10_3310_hta24020
crossref_primary_10_1007_s40261_014_0174_5
crossref_primary_10_1016_j_ctrv_2014_02_004
crossref_primary_10_1042_CS20200307
crossref_primary_10_1093_jncics_pkaa076
crossref_primary_10_1080_17512433_2019_1689122
crossref_primary_10_1097_MD_0000000000015806
crossref_primary_10_1016_j_biopha_2022_113962
crossref_primary_10_1186_s40959_015_0009_4
crossref_primary_10_1080_1120009X_2021_1955202
crossref_primary_10_1007_s00228_013_1598_1
crossref_primary_10_1016_j_cld_2020_07_008
crossref_primary_10_1038_s41598_018_23630_w
crossref_primary_10_1007_s11523_017_0522_5
crossref_primary_10_34883_PI_2020_12_2_009
crossref_primary_10_2217_fon_14_42
crossref_primary_10_3389_fcvm_2022_986570
crossref_primary_10_1038_s41371_020_0391_8
crossref_primary_10_1111_bcpt_12365
crossref_primary_10_1371_journal_pone_0090135
crossref_primary_10_1007_s00520_016_3310_3
Cites_doi 10.1161/01.HYP.0000107251.49515.c2
10.1200/jco.2009.27.15_suppl.6058
10.1002/cncr.25448
10.1172/JCI118838
10.1016/j.jclinepi.2009.06.005
10.1200/JCO.2009.26.7856
10.1007/s10637-012-9795-9
10.1200/JCO.2007.15.5242
10.1200/jco.2008.26.15_suppl.10502
10.1371/journal.pone.0026331
10.1200/JCO.2008.16.3279
10.1200/jco.2012.30.15_suppl.4503
10.1097/CAD.0b013e32832b2ea0
10.1200/jco.2011.29.15_suppl.10009
10.1200/jco.2008.26.15_suppl.8014
10.1200/jco.2012.30.15_suppl.4546
10.1158/1078-0432.CCR-07-5050
10.1093/annonc/mdm554
10.1111/j.1464-410X.2008.08327.x
10.1111/j.1464-410X.2011.10421.x
10.1158/1078-0432.CCR-10-2331
10.1200/JCO.2011.39.7646
10.1200/jco.2011.29.15_suppl.4028
10.1016/j.ygyno.2010.01.013
10.1001/jama.2010.1672
10.1371/journal.pone.0015588
10.1093/jnci/djm311
10.1002/cncr.26334
10.1073/pnas.041359198
10.1158/0008-5472.CAN-04-1443
10.1200/JCO.2009.22.0541
10.1016/S0090-4295(02)01501-7
10.1016/j.ejca.2011.05.007
10.1200/JCO.2009.22.6480
10.1002/cncr.24685
10.1016/S0140-6736(02)11911-8
10.1016/j.cell.2007.06.054
10.1016/S1470-2045(09)70222-0
10.1007/s12094-010-0544-2
10.1634/theoncologist.2011-0237
10.1016/S1470-2045(08)70003-2
10.1158/1078-0432.CCR-07-1355
10.1016/S0140-6736(11)61613-9
10.1158/1078-0432.CCR-09-0058
10.1016/S1470-2045(08)70009-3
10.1016/S1470-2045(08)70285-7
10.1200/JCO.2009.26.1321
10.1093/annonc/mdm550
10.1200/JCO.2009.25.0068
10.1016/j.eururo.2006.06.026
10.1038/sj.bjc.6603291
10.1016/j.critrevonc.2010.11.007
10.1002/cncr.25327
10.1158/2159-8274.CD-10-0010
10.1200/jco.2012.30.15_suppl.4539
10.1200/JCO.2005.03.6723
10.1097/JTO.0b013e3181ec18db
10.1200/JCO.2010.30.7678
10.1111/j.1440-1681.2012.05699.x
10.1200/jco.2007.25.18_suppl.4504
10.1080/02841860802314720
10.1200/JCO.2008.20.4495
10.1056/NEJMoa060655
10.1016/S0014-5793(97)01481-6
10.1200/JCO.2009.22.2273
10.1158/1535-7163.MCT-08-0013
10.1200/JCO.2011.36.7771
10.1200/JCO.2009.25.6834
10.1093/annonc/mdr151
10.1056/NEJMoa0708857
10.1200/JCO.2008.18.2717
10.1016/j.urolonc.2008.06.003
10.1200/JCO.2009.24.7759
10.1200/jco.2012.30.4_suppl.lba154
10.1530/EJE-09-0702
10.1200/JCO.2009.27.2757
10.1038/sj.bjc.6604064
10.1161/01.ATV.17.11.2793
10.4103/0019-509X.75825
10.1158/0008-5472.CAN-08-0851
10.1159/000338175
10.1038/bjc.2011.103
10.1002/cncr.24029
10.1530/EJE-11-0129
10.1200/JCO.2008.19.5511
10.3816/CGC.2009.n.002
10.1200/JCO.2007.14.8288
10.1200/JCO.2006.10.2871
10.1080/02841860701765675
10.1200/JCO.2008.19.3342
10.1200/jco.2012.30.15_suppl.4501
10.1200/JCO.2006.08.4608
10.1111/j.1464-410X.2011.10281.x
10.1200/jco.2012.30.15_suppl.10020
10.1161/01.CIR.0000061911.47710.8A
10.1093/jjco/hym095
ContentType Journal Article
Copyright Macmillan Publishers Limited 2013
COPYRIGHT 2013 Nature Publishing Group
Copyright Nature Publishing Group Oct 2013
Macmillan Publishers Limited 2013.
Copyright_xml – notice: Macmillan Publishers Limited 2013
– notice: COPYRIGHT 2013 Nature Publishing Group
– notice: Copyright Nature Publishing Group Oct 2013
– notice: Macmillan Publishers Limited 2013.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8AO
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1038/jhh.2013.30
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni)
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

ProQuest Central Student

MEDLINE


ProQuest Central Student
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1476-5527
EndPage 611
ExternalDocumentID 3068228561
A346139896
23636006
10_1038_jhh_2013_30
Genre Meta-Analysis
Systematic Review
Journal Article
GroupedDBID ---
-Q-
0R~
29K
2WC
36B
39C
3V.
4.4
406
5GY
5RE
70F
7X7
88E
8AO
8FI
8FJ
8R4
8R5
A8Z
AANZL
AAYZH
AAZLF
ABAKF
ABAWZ
ABCQX
ABDBF
ABJNI
ABLJU
ABOCM
ABUWG
ABZZP
ACAOD
ACGFS
ACKTT
ACPRK
ACRQY
ACUHS
ACZOJ
ADBBV
ADHDB
AEFQL
AEJRE
AEMSY
AENEX
AEVLU
AEXYK
AFBBN
AFKRA
AFSHS
AGAYW
AGHAI
AGQEE
AHMBA
AHSBF
AILAN
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
AXYYD
B0M
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CCPQU
CS3
D-I
DIK
DNIVK
DPUIP
DU5
E3Z
EAD
EAP
EBC
EBD
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
FDQFY
FERAY
FIZPM
FSGXE
FYUFA
HCIFZ
HMCUK
HZ~
IAO
IHR
IHW
INH
INR
ITC
IWAJR
JSO
JZLTJ
KQ8
L7B
M1P
M7P
NAO
NQJWS
O9-
OK1
OVD
P2P
PQQKQ
PROAC
PSQYO
Q2X
RNT
RNTTT
ROL
SNX
SNYQT
SOHCF
SOJ
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TEORI
TSG
TUS
UKHRP
W2D
~8M
AASML
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
AEZWR
AFDZB
AFHIU
AHWEU
AIGIU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
53G
AACDK
AATNV
ABRTQ
BAWUL
CAG
CGR
COF
CUY
CVF
ECM
EIF
FIGPU
NPM
PJZUB
PPXIY
PQGLB
RNS
TR2
YYP
ZXP
AEIIB
PMFND
7T5
7XB
8FE
8FH
8FK
AZQEC
DWQXO
GNUQQ
H94
K9.
LK8
PKEHL
PQEST
PQUKI
PRINS
PUEGO
7X8
ID FETCH-LOGICAL-c480t-126253ccf2488a0c7f33aba4ffd12b414fd9909a2a4819a5675ab4e8bcc35acc3
IEDL.DBID 7X7
ISSN 0950-9240
1476-5527
IngestDate Thu Jul 10 23:52:44 EDT 2025
Sat Aug 23 14:26:02 EDT 2025
Fri Jul 25 09:09:06 EDT 2025
Tue Jun 17 21:43:36 EDT 2025
Tue Jun 10 20:44:04 EDT 2025
Thu May 22 21:03:55 EDT 2025
Mon Jul 21 05:39:59 EDT 2025
Thu Apr 24 23:13:28 EDT 2025
Tue Jul 01 03:25:30 EDT 2025
Fri Feb 21 02:39:49 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords meta-analysis
cancer
sorafenib
hypertension
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c480t-126253ccf2488a0c7f33aba4ffd12b414fd9909a2a4819a5675ab4e8bcc35acc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
PMID 23636006
PQID 1431395577
PQPubID 35973
PageCount 11
ParticipantIDs proquest_miscellaneous_1432074583
proquest_journals_2640658918
proquest_journals_1431395577
gale_infotracmisc_A346139896
gale_infotracacademiconefile_A346139896
gale_healthsolutions_A346139896
pubmed_primary_23636006
crossref_primary_10_1038_jhh_2013_30
crossref_citationtrail_10_1038_jhh_2013_30
springer_journals_10_1038_jhh_2013_30
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20131001
2013-10-01
2013-Oct
PublicationDateYYYYMMDD 2013-10-01
PublicationDate_xml – month: 10
  year: 2013
  text: 20131001
  day: 1
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Journal of human hypertension
PublicationTitleAbbrev J Hum Hypertens
PublicationTitleAlternate J Hum Hypertens
PublicationYear 2013
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Procopio, Verzoni, Bracarda, Ricci, Sacco, Ridolfi (CR56) 2011; 104
Chobanian, Bakris, Black, Cushman, Green, Izzo (CR16) 2003; 42
Kudo, Imanaka, Chida, Nakachi, Tak, Takayama (CR45) 2011; 47
Hood, Meininger, Ziche, Granger (CR19) 1998; 274
CR39
Naito, Tsukamoto, Murai, Fukino, Akaza (CR94) 2011; 108
CR37
Mancuso, Di Paola, Leone, Catalano, Calabro, Cerbone (CR99) 2012; 109
Michaelson, Rini, Escudier, Clark, Redman, Tarazi (CR47) 2012; 30
Gupta-Abramson, Troxel, Nellore, Puttaswamy, Redlinger, Ransone (CR71) 2008; 26
Khakoo, Sidman, Pasqualini, Arap (CR31) 2008; 68
Chu, Lacouture, Weiner, Wu (CR4) 2009; 7
Lee, Chen, Barber, Jordan, Murdock, Desai (CR24) 2007; 130
Cheng, Kang, Chen, Tsao, Qin, Kim (CR42) 2009; 10
Nagaiah, Fu, Wasman, Cooney, Mooney, Afshin (CR77) 2009; 27
Maki, D'Adamo, Keohan, Saulle, Schuetze, Undevia (CR78) 2009; 27
Nimeiri, Oza, Morgan, Huo, Elit, Knost (CR83) 2010; 117
Raut, Boucher, Duda, Morgan, Quek, Ancukiewicz (CR102) 2012; 7
Choueiri, Schutz, Je, Rosenberg, Bellmunt (CR7) 2010; 28
Wiebe, Kasza, Maki, D'Adamo, Chow, Wade (CR70) 2008; 26
Chu, Lacouture, Fillos, Wu (CR5) 2008; 47
Lam, Ringel, Kloos, Prior, Knopp, Liang (CR85) 2010; 28
Steinbild, Mross, Frost, Morant, Gillessen, Dittrich (CR66) 2007; 97
Jonasch, Corn, Pagliaro, Warneke, Johnson, Tamboli (CR53) 2010; 116
McKiernan, Simmons, Katz, Russo (CR18) 2002; 59
Kindler, Campbell, Wroblewski, Maki, D’Adamo, Chow (CR96) 2011; 29
Steeghs, Gelderblom, Roodt, Christensen, Rajagopalan, Hovens (CR25) 2008; 14
Dubey, Janne, Krug, Pang, Wang, Heinze (CR88) 2010; 5
Scagliotti, Novello, von Pawel, Reck, Pereira, Thomas (CR43) 2010; 28
Chi, Ellard, Hotte, Czaykowski, Moore, Ruether (CR67) 2008; 19
von Mehren, Rankin, Goldblum, Demetri, Bramwell, Ryan (CR98) 2012; 118
Dy, Hillman, Rowland, Molina, Steen, Wender (CR92) 2010; 116
Hobday, Rubin, Holen, Picus, Donehower, Marschke (CR63) 2007; Vol 25
Je, Schutz, Choueiri (CR6) 2009; 10
Ott, Hamilton, Min, Safarzadeh-Amiri, Goldberg, Yoon (CR91) 2010; 5
Kelly, Rajan, Force, Lopez-Chavez, Keen, Cao (CR93) 2011; 17
Escudier, Eisen, Stadler, Szczylik, Oudard, Staehler (CR40) 2009; 27
Moher, Liberati, Tetzlaff, Altman (CR13) 2009; 62
Yau, Chan, Ng, Chok, Cheung, Fan (CR74) 2009; 115
Nagasawa, Hye Khan, Imig (CR34) 2012; 39
Rini, Escudier, Tomczak, Kaprin, Szczylik, Hutson (CR46) 2011; 378
Patel, Morgan, Demetri, George, Maki, Quigley (CR30) 2008; 100
Eisen, Ahmad, Flaherty, Gore, Kaye, Marais (CR62) 2006; 95
Wilhelm, Carter, Tang, Wilkie, McNabola, Rong (CR1) 2004; 64
Michel, Vervenne, Goebell, Von Weikersthal, Freier, De Santis (CR48) 2012; 30
Matei, Sill, Lankes, DeGeest, Bristow, Mutch (CR90) 2011; 29
Henry, Annex, McKendall, Azrin, Lopez, Giordano (CR22) 2003; 107
Hoftijzer, Heemstra, Morreau, Stokkel, Corssmit, Gelderblom (CR82) 2009; 161
Wu, Chen, Kudelka, Lu, Zhu (CR11) 2008; 9
Goncalves, Viret, François, Dahan, Perrier, Lamy (CR44) 2011; 29
Moreno-Aspitia, Morton, Hillman, Lingle, Rowland, Wiesenfeld (CR73) 2009; 27
Safarinejad (CR72) 2010; 28
Dahut, Scripture, Posadas, Jain, Gulley, Arlen (CR68) 2008; 14
Horowitz, Rivard, van der Zee, Hariawala, Sheriff, Esakof (CR21) 1997; 17
Escudier, Eisen, Stadler, Szczylik, Oudard, Siebels (CR28) 2007; 356
Wilhelm, Adnane, Newell, Villanueva, Llovet, Lynch (CR2) 2008; 7
Motzer, Nosov, Eisen, Bondarenko, Lesovoy, Lipatov (CR49) 2012; 30
Di Lorenzo, Carteni, Autorino, Bruni, Tudini, Rizzo (CR79) 2009; 27
Blumenschein, Gatzemeier, Fossella, Stewart, Cupit, Cihon (CR80) 2009; 27
Ray-Coquard, Italiano, Bompas, Le Cesne, Robin, Chevreau (CR101) 2012; 17
Zhu, Stergiopoulos, Wu (CR10) 2009; 48
Wheeler-Jones, Abu-Ghazaleh, Cospedal, Houliston, Martin, Zachary (CR20) 1997; 420
Ahmed, Barbachano, Riddell, Hickey, Newbold, Viros (CR97) 2011; 165
Schutz, Je, Choueiri (CR8) 2011; 80
Baselga, Segalla, Roche, Del Giglio, Pinczowski, Ciruelos (CR59) 2012; 30
McDermott, Sosman, Gonzalez, Hodi, Linette, Richards (CR51) 2008; 26
Aragon-Ching, Jain, Gulley, Arlen, Wright, Steinberg (CR75) 2009; 103
Mourad, des Guetz, Debbabi, Levy (CR26) 2008; 19
CR3
Paz-Ares, Biesma, Heigener, von Pawel, Eisen, Bennouna (CR50) 2012; 30
Langenberg, van Herpen, De Bono, Schellens, Unger, Hoekman (CR35) 2009; 27
CR9
Lencioni, Llovet, Han, Tak, Yang, Leberre (CR60) 2012; 30
Maitland, Kasza, Karrison, Moshier, Sit, Black (CR23) 2009; 15
Lewington, Clarke, Qizilbash, Peto, Collins (CR27) 2002; 360
Williamson, Moon, Huang, Guaglianone, LeBlanc, Wolf (CR86) 2010; 28
Park, Ryu, Ryoo, Im, Kwon, Lee (CR100) 2012; 30
Cowey, Amin, Pruthi, Wallen, Nielsen, Grigson (CR84) 2010; 28
Escudier, Szczylik, Hutson, Demkow, Staehler, Rolland (CR52) 2009; 27
Schiller, Lee, Hanna, Traynor, Carbone (CR69) 2008; 26
Chevreau, Le Cesne, Ray-Coquard, Nguyen, Bompas, Isambert (CR103) 2012; 30
Llovet, Ricci, Mazzaferro, Hilgard, Gane, Blanc (CR41) 2008; 359
Govindarajan, Adusumilli, Baxter, El-Khoueiry, Harik (CR29) 2006; 24
Ratain, Eisen, Stadler, Flaherty, Kaye, Rosner (CR61) 2006; 24
Szmit, Zaborowska, Wasko-Grabowska, Zolnierek, Nurzynski, Filipiak (CR38) 2012; 35
CR15
CR14
Garcia, Hutson, Elson, Cowey, Gilligan, Nemec (CR89) 2010; 116
Galal, Khaled, Mourad (CR55) 2011; 48
Grignani, Palmerini, Dileo, Asaftei, D'Ambrosio, Pignochino (CR95) 2012; 23
Schips, Dalpiaz, Lipsky, Langner, Rehak, Puerstner (CR17) 2007; 51
Volpert, Ward, Lingen, Chesler, Solt, Johnson (CR32) 1996; 98
Kloos, Ringel, Knopp, Hall, King, Stevens (CR76) 2009; 27
Abou-Alfa, Johnson, Knox, Capanu, Davidenko, Lacava (CR54) 2010; 304
Yoshiji, Kuriyama, Kawata, Yoshii, Ikenaka, Noguchi (CR33) 2001; 7
Spigel, Burris, Greco, Shipley, Friedman, Waterhouse (CR58) 2011; 29
Bianchi, Loibl, Zamagni, Salvagni, Raab, Siena (CR81) 2009; 20
Akaza, Tsukamoto, Murai, Nakajima, Naito (CR65) 2007; 37
Rini (CR12) 2008; 9
Bellmunt, Maroto-Rey, Trigo, Carles, Guillem, Lopez-Martin (CR87) 2010; 12
Fukumura, Gohongi, Kadambi, Izumi, Ang, Yun (CR36) 2001; 98
Elser, Siu, Winquist, Agulnik, Pond, Chin (CR64) 2007; 25
Kim, Herbst, Wistuba, Lee, Blumenschein, Tsao (CR57) 2011; 1
G Di Lorenzo (BFjhh201330_CR79) 2009; 27
M Ahmed (BFjhh201330_CR97) 2011; 165
WL Dahut (BFjhh201330_CR68) 2008; 14
D Chu (BFjhh201330_CR5) 2008; 47
CP Raut (BFjhh201330_CR102) 2012; 7
JA Garcia (BFjhh201330_CR89) 2010; 116
H Yoshiji (BFjhh201330_CR33) 2001; 7
MR Safarinejad (BFjhh201330_CR72) 2010; 28
B Escudier (BFjhh201330_CR40) 2009; 27
J McKiernan (BFjhh201330_CR18) 2002; 59
H Hoftijzer (BFjhh201330_CR82) 2009; 161
ES Kim (BFjhh201330_CR57) 2011; 1
J Baselga (BFjhh201330_CR59) 2012; 30
S Lewington (BFjhh201330_CR27) 2002; 360
D Moher (BFjhh201330_CR13) 2009; 62
DR Spigel (BFjhh201330_CR58) 2011; 29
A Mancuso (BFjhh201330_CR99) 2012; 109
S Lee (BFjhh201330_CR24) 2007; 130
FA Schutz (BFjhh201330_CR8) 2011; 80
M Kudo (BFjhh201330_CR45) 2011; 47
G Procopio (BFjhh201330_CR56) 2011; 104
JJ Mourad (BFjhh201330_CR26) 2008; 19
SM Wilhelm (BFjhh201330_CR1) 2004; 64
KM Galal (BFjhh201330_CR55) 2011; 48
C Elser (BFjhh201330_CR64) 2007; 25
PA Ott (BFjhh201330_CR91) 2010; 5
MD Michaelson (BFjhh201330_CR47) 2012; 30
G Nagaiah (BFjhh201330_CR77) 2009; 27
E Jonasch (BFjhh201330_CR53) 2010; 116
G Scagliotti (BFjhh201330_CR43) 2010; 28
M von Mehren (BFjhh201330_CR98) 2012; 118
AY Khakoo (BFjhh201330_CR31) 2008; 68
LG Paz-Ares (BFjhh201330_CR50) 2012; 30
CL Cowey (BFjhh201330_CR84) 2010; 28
SM Wilhelm (BFjhh201330_CR2) 2008; 7
S Szmit (BFjhh201330_CR38) 2012; 35
T Yau (BFjhh201330_CR74) 2009; 115
SH Park (BFjhh201330_CR100) 2012; 30
X Zhu (BFjhh201330_CR10) 2009; 48
D Matei (BFjhh201330_CR90) 2011; 29
HS Nimeiri (BFjhh201330_CR83) 2010; 117
R Govindarajan (BFjhh201330_CR29) 2006; 24
TD Henry (BFjhh201330_CR22) 2003; 107
SK Williamson (BFjhh201330_CR86) 2010; 28
HL Kindler (BFjhh201330_CR96) 2011; 29
T Nagasawa (BFjhh201330_CR34) 2012; 39
S Steinbild (BFjhh201330_CR66) 2007; 97
JB Aragon-Ching (BFjhh201330_CR75) 2009; 103
BI Rini (BFjhh201330_CR12) 2008; 9
D Fukumura (BFjhh201330_CR36) 2001; 98
A Goncalves (BFjhh201330_CR44) 2011; 29
T Eisen (BFjhh201330_CR62) 2006; 95
S Dubey (BFjhh201330_CR88) 2010; 5
V Gupta-Abramson (BFjhh201330_CR71) 2008; 26
L Schips (BFjhh201330_CR17) 2007; 51
MS Michel (BFjhh201330_CR48) 2012; 30
R Lencioni (BFjhh201330_CR60) 2012; 30
G Bianchi (BFjhh201330_CR81) 2009; 20
RJ Motzer (BFjhh201330_CR49) 2012; 30
MH Langenberg (BFjhh201330_CR35) 2009; 27
BFjhh201330_CR39
JH Schiller (BFjhh201330_CR69) 2008; 26
S Naito (BFjhh201330_CR94) 2011; 108
Y Je (BFjhh201330_CR6) 2009; 10
MJ Ratain (BFjhh201330_CR61) 2006; 24
S Wu (BFjhh201330_CR11) 2008; 9
AV Chobanian (BFjhh201330_CR16) 2003; 42
JR Horowitz (BFjhh201330_CR21) 1997; 17
BFjhh201330_CR37
JM Llovet (BFjhh201330_CR41) 2008; 359
I Ray-Coquard (BFjhh201330_CR101) 2012; 17
D Chu (BFjhh201330_CR4) 2009; 7
GK Abou-Alfa (BFjhh201330_CR54) 2010; 304
J Bellmunt (BFjhh201330_CR87) 2010; 12
ML Maitland (BFjhh201330_CR23) 2009; 15
GR Blumenschein Jr. (BFjhh201330_CR80) 2009; 27
GK Dy (BFjhh201330_CR92) 2010; 116
TK Choueiri (BFjhh201330_CR7) 2010; 28
BFjhh201330_CR9
G Grignani (BFjhh201330_CR95) 2012; 23
OV Volpert (BFjhh201330_CR32) 1996; 98
BFjhh201330_CR3
DF McDermott (BFjhh201330_CR51) 2008; 26
C Chevreau (BFjhh201330_CR103) 2012; 30
C Wheeler-Jones (BFjhh201330_CR20) 1997; 420
H Akaza (BFjhh201330_CR65) 2007; 37
JD Hood (BFjhh201330_CR19) 1998; 274
L Wiebe (BFjhh201330_CR70) 2008; 26
RG Maki (BFjhh201330_CR78) 2009; 27
A Moreno-Aspitia (BFjhh201330_CR73) 2009; 27
TV Patel (BFjhh201330_CR30) 2008; 100
KN Chi (BFjhh201330_CR67) 2008; 19
RT Kloos (BFjhh201330_CR76) 2009; 27
TJ Hobday (BFjhh201330_CR63) 2007; Vol 25
N Steeghs (BFjhh201330_CR25) 2008; 14
ET Lam (BFjhh201330_CR85) 2010; 28
BFjhh201330_CR15
BFjhh201330_CR14
B Escudier (BFjhh201330_CR28) 2007; 356
B Escudier (BFjhh201330_CR52) 2009; 27
BI Rini (BFjhh201330_CR46) 2011; 378
RJ Kelly (BFjhh201330_CR93) 2011; 17
AL Cheng (BFjhh201330_CR42) 2009; 10
References_xml – volume: 48
  start-page: 9
  issue: 1
  year: 2009
  end-page: 17
  ident: CR10
  article-title: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis
  publication-title: Acta Oncol
– volume: 64
  start-page: 7099
  issue: 19
  year: 2004
  end-page: 7109
  ident: CR1
  article-title: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
  publication-title: Cancer Res
– volume: 29
  start-page: abstr 4028
  issue: suppl
  year: 2011
  ident: CR44
  article-title: BAYPAN study: a double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer
  publication-title: J Clin Oncol
– volume: 161
  start-page: 923
  issue: 6
  year: 2009
  end-page: 931
  ident: CR82
  article-title: Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
  publication-title: Eur J Endocrinol
– volume: 7
  start-page: 3129
  issue: 10
  year: 2008
  end-page: 3140
  ident: CR2
  article-title: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
  publication-title: Mol Cancer Ther
– ident: CR39
– volume: 107
  start-page: 1359
  issue: 10
  year: 2003
  end-page: 1365
  ident: CR22
  article-title: The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis
  publication-title: Circulation
– volume: 30
  start-page: abstr 4501
  issue: suppl
  year: 2012
  ident: CR49
  article-title: Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial
  publication-title: J Clin Oncol
– volume: 80
  start-page: 291
  issue: 2
  year: 2011
  end-page: 300
  ident: CR8
  article-title: Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials
  publication-title: Crit Rev Oncol Hematol
– volume: 27
  start-page: 1280
  issue: 8
  year: 2009
  end-page: 1289
  ident: CR52
  article-title: Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma
  publication-title: J Clin Oncol
– volume: 48
  start-page: 47
  issue: 1
  year: 2011
  end-page: 54
  ident: CR55
  article-title: Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer
  publication-title: Indian J Cancer
– volume: 14
  start-page: 3470
  issue: 11
  year: 2008
  end-page: 3476
  ident: CR25
  article-title: Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor
  publication-title: Clin Cancer Res
– volume: 98
  start-page: 671
  issue: 3
  year: 1996
  end-page: 679
  ident: CR32
  article-title: Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats
  publication-title: J Clin Invest
– volume: 39
  start-page: 454
  issue: 5
  year: 2012
  end-page: 461
  ident: CR34
  article-title: Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib
  publication-title: Clin Exp Pharmacol Physiol
– volume: 116
  start-page: 57
  issue: 1
  year: 2010
  end-page: 65
  ident: CR53
  article-title: Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis
  publication-title: Cancer
– volume: 116
  start-page: 5686
  issue: 24
  year: 2010
  end-page: 5693
  ident: CR92
  article-title: A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326
  publication-title: Cancer
– volume: 274
  start-page: H1054
  issue: 3 Pt 2
  year: 1998
  end-page: H1058
  ident: CR19
  article-title: VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
  publication-title: Am J Physiol
– volume: 27
  start-page: 3312
  issue: 20
  year: 2009
  end-page: 3318
  ident: CR40
  article-title: Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
  publication-title: J Clin Oncol
– volume: 29
  start-page: 2582
  issue: 18
  year: 2011
  end-page: 2589
  ident: CR58
  article-title: Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer
  publication-title: J Clin Oncol
– volume: 29
  start-page: 69
  issue: 1
  year: 2011
  end-page: 75
  ident: CR90
  article-title: Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial
  publication-title: J clin Oncol
– volume: 26
  start-page: abstr 10502
  issue: suppl
  year: 2008
  ident: CR70
  article-title: Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium
  publication-title: J Clin Oncol
– volume: 12
  start-page: 503
  issue: 7
  year: 2010
  end-page: 508
  ident: CR87
  article-title: A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01
  publication-title: Clin Transl Oncol
– volume: 27
  start-page: 6152
  issue: 36
  year: 2009
  end-page: 6159
  ident: CR35
  article-title: Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors
  publication-title: J Clin Oncol
– volume: 47
  start-page: 176
  issue: 2
  year: 2008
  end-page: 186
  ident: CR5
  article-title: Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis
  publication-title: Acta Oncol
– volume: 5
  start-page: 1655
  issue: 10
  year: 2010
  end-page: 1661
  ident: CR88
  article-title: A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307
  publication-title: J Thorac Oncol
– volume: 28
  start-page: 3330
  issue: 20
  year: 2010
  end-page: 3335
  ident: CR86
  article-title: Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420
  publication-title: J Clin Oncol
– volume: 9
  start-page: 117
  issue: 2
  year: 2008
  end-page: 123
  ident: CR11
  article-title: Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
  publication-title: Lancet Oncol
– volume: 9
  start-page: 86
  issue: 2
  year: 2008
  end-page: 87
  ident: CR12
  article-title: Quantifying hypertension in patients with cancer treated with sorafenib
  publication-title: Lancet Oncol
– volume: 378
  start-page: 1931
  issue: 9807
  year: 2011
  end-page: 1939
  ident: CR46
  article-title: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
  publication-title: Lancet
– volume: 15
  start-page: 6250
  issue: 19
  year: 2009
  end-page: 6257
  ident: CR23
  article-title: Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment
  publication-title: Clin Cancer Res
– volume: 20
  start-page: 616
  issue: 7
  year: 2009
  end-page: 624
  ident: CR81
  article-title: Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
  publication-title: Anticancer Drugs
– volume: 117
  start-page: 37
  issue: 1
  year: 2010
  end-page: 40
  ident: CR83
  article-title: A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia
  publication-title: Gynecol Oncol
– volume: 30
  start-page: abstr 10020
  issue: suppl
  year: 2012
  ident: CR103
  article-title: Phase II study of sorafenib mesylate (So) in patients (pts) with evolutive and advanced epithelioid hemangioendothelioma (EHE) or hemangiopericytoma/solitary fibrous tumor (SFT)
  publication-title: J Clin Oncol
– volume: 27
  start-page: 1675
  issue: 10
  year: 2009
  end-page: 1684
  ident: CR76
  article-title: Phase II trial of sorafenib in metastatic thyroid cancer
  publication-title: J Clin Oncol
– volume: 28
  start-page: 21
  issue: 1
  year: 2010
  end-page: 27
  ident: CR72
  article-title: Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study
  publication-title: Urol Oncol
– volume: 130
  start-page: 691
  issue: 4
  year: 2007
  end-page: 703
  ident: CR24
  article-title: Autocrine VEGF signaling is required for vascular homeostasis
  publication-title: Cell
– volume: 104
  start-page: 1256
  issue: 8
  year: 2011
  end-page: 1261
  ident: CR56
  article-title: Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
  publication-title: Br Jo Cancer
– volume: 97
  start-page: 1480
  issue: 11
  year: 2007
  end-page: 1485
  ident: CR66
  article-title: A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
  publication-title: Br J Cancer
– ident: CR3
– volume: 24
  start-page: e48
  issue: 28
  year: 2006
  ident: CR29
  article-title: Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006
  publication-title: J Clin Oncol
– volume: 359
  start-page: 378
  issue: 4
  year: 2008
  end-page: 390
  ident: CR41
  article-title: Sorafenib in advanced hepatocellular carcinoma
  publication-title: N Engl J Med
– volume: 30
  start-page: abstr LBA154
  issue: suppl 4
  year: 2012
  ident: CR60
  article-title: Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial
  publication-title: J Clin Oncol
– volume: 51
  start-page: 168
  issue: 1
  year: 2007
  end-page: 173
  ident: CR17
  article-title: Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group
  publication-title: Eur Urol
– volume: 59
  start-page: 816
  issue: 6
  year: 2002
  end-page: 820
  ident: CR18
  article-title: Natural history of chronic renal insufficiency after partial and radical nephrectomy
  publication-title: Urology
– volume: 30
  start-page: 3084
  issue: 25
  year: 2012
  end-page: 3092
  ident: CR50
  article-title: Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer
  publication-title: J Clin Oncol
– volume: 30
  start-page: 2377
  issue: 6
  year: 2012
  end-page: 2383
  ident: CR100
  article-title: Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
  publication-title: Invest New Drugs
– volume: 42
  start-page: 1206
  issue: 6
  year: 2003
  end-page: 1252
  ident: CR16
  article-title: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
  publication-title: Hypertension
– volume: 27
  start-page: 3133
  issue: 19
  year: 2009
  end-page: 3140
  ident: CR78
  article-title: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
  publication-title: J Clin Oncol
– volume: 27
  start-page: 11
  issue: 1
  year: 2009
  end-page: 15
  ident: CR73
  article-title: Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
  publication-title: J Clin Oncol
– volume: 29
  start-page: abstr 10009
  issue: suppl
  year: 2011
  ident: CR96
  article-title: Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago Phase II Consortium trial
  publication-title: J Clin Oncol
– volume: 14
  start-page: 209
  issue: 1
  year: 2008
  end-page: 214
  ident: CR68
  article-title: A phase II clinical trial of sorafenib in androgen-independent prostate cancer
  publication-title: Clin Cancer Res
– volume: 10
  start-page: 25
  issue: 1
  year: 2009
  end-page: 34
  ident: CR42
  article-title: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
  publication-title: Lancet Oncol
– volume: 27
  start-page: 4469
  issue: 27
  year: 2009
  end-page: 4474
  ident: CR79
  article-title: Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer
  publication-title: J Clin OncolJ
– volume: 116
  start-page: 5383
  issue: 23
  year: 2010
  end-page: 5390
  ident: CR89
  article-title: Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab
  publication-title: Cancer
– volume: 23
  start-page: 508
  issue: 2
  year: 2012
  end-page: 516
  ident: CR95
  article-title: A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
  publication-title: Ann Oncol
– volume: 28
  start-page: 2280
  issue: 13
  year: 2010
  end-page: 2285
  ident: CR7
  article-title: Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
  publication-title: J Clin Oncol
– volume: 5
  start-page: e15588
  issue: 12
  year: 2010
  ident: CR91
  article-title: A phase II trial of sorafenib in metastatic melanoma with tissue correlates
  publication-title: PloS One
– volume: 360
  start-page: 1903
  issue: 9349
  year: 2002
  end-page: 1913
  ident: CR27
  article-title: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
  publication-title: Lancet
– volume: 108
  start-page: 1813
  issue: 11
  year: 2011
  end-page: 1819
  ident: CR94
  article-title: Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma
  publication-title: BJU Int
– volume: 30
  start-page: abstr 4546
  issue: suppl
  year: 2012
  ident: CR47
  article-title: Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma: Updated results among cytokine-treated patients
  publication-title: J Clin Oncol
– volume: 30
  start-page: 1484
  issue: 13
  year: 2012
  end-page: 1491
  ident: CR59
  article-title: Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer
  publication-title: J Clin Oncol
– volume: 356
  start-page: 125
  issue: 2
  year: 2007
  end-page: 134
  ident: CR28
  article-title: Sorafenib in advanced clear-cell renal-cell carcinoma
  publication-title: N Engl J Med
– volume: 25
  start-page: 3766
  issue: 24
  year: 2007
  end-page: 3773
  ident: CR64
  article-title: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma
  publication-title: J Clin Oncol
– volume: 10
  start-page: 967
  issue: 10
  year: 2009
  end-page: 974
  ident: CR6
  article-title: Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
  publication-title: Lancet Oncol
– volume: 37
  start-page: 755
  issue: 10
  year: 2007
  end-page: 762
  ident: CR65
  article-title: Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma
  publication-title: Jpn J Clin Oncol
– ident: CR15
– volume: 24
  start-page: 2505
  issue: 16
  year: 2006
  end-page: 2512
  ident: CR61
  article-title: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
  publication-title: J Clin Oncol
– volume: 28
  start-page: 1502
  issue: 9
  year: 2010
  end-page: 1507
  ident: CR84
  article-title: Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma
  publication-title: J Clin Oncol
– ident: CR9
– volume: 68
  start-page: 9112
  issue: 22
  year: 2008
  end-page: 9115
  ident: CR31
  article-title: Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis?
  publication-title: Cancer Res
– volume: 7
  start-page: e26331
  issue: 2
  year: 2012
  ident: CR102
  article-title: Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)
  publication-title: PloS One
– volume: 47
  start-page: 2117
  issue: 14
  year: 2011
  end-page: 2127
  ident: CR45
  article-title: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
  publication-title: Eur J Cancer
– volume: Vol 25
  start-page: 4504
  issue: No. 18S
  year: 2007
  ident: CR63
  article-title: MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study
  publication-title: J Clin Oncol
– volume: 19
  start-page: 927
  issue: 5
  year: 2008
  end-page: 934
  ident: CR26
  article-title: Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
  publication-title: Ann Oncol
– volume: 98
  start-page: 2604
  issue: 5
  year: 2001
  end-page: 2609
  ident: CR36
  article-title: Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability
  publication-title: Proc Natl Acad Sci USA
– volume: 27
  start-page: abstr 6058
  issue: suppl
  year: 2009
  ident: CR77
  article-title: Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC)
  publication-title: J Clin Oncol
– volume: 103
  start-page: 1636
  issue: 12
  year: 2009
  end-page: 1640
  ident: CR75
  article-title: Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
  publication-title: BJU Int
– ident: CR14
– volume: 26
  start-page: 2178
  issue: 13
  year: 2008
  end-page: 2185
  ident: CR51
  article-title: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
  publication-title: J Clin Oncol
– ident: CR37
– volume: 26
  start-page: abstr 8014
  issue: suppl
  year: 2008
  ident: CR69
  article-title: A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501
  publication-title: J Clin Oncol
– volume: 100
  start-page: 282
  issue: 4
  year: 2008
  end-page: 284
  ident: CR30
  article-title: A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
  publication-title: J Natl Cancer Inst
– volume: 17
  start-page: 260
  issue: 2
  year: 2012
  end-page: 266
  ident: CR101
  article-title: Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO)
  publication-title: Oncologist
– volume: 28
  start-page: 2323
  issue: 14
  year: 2010
  end-page: 2330
  ident: CR85
  article-title: Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer
  publication-title: J Clin Oncol
– volume: 17
  start-page: 2793
  issue: 11
  year: 1997
  end-page: 2800
  ident: CR21
  article-title: Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium
  publication-title: Arterioscler Thromb Vasc Biol
– volume: 17
  start-page: 1190
  issue: 5
  year: 2011
  end-page: 1199
  ident: CR93
  article-title: Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib
  publication-title: Clin Cancer Res
– volume: 30
  start-page: abstr 4539
  issue: suppl
  year: 2012
  ident: CR48
  article-title: Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): safety interim analysis results
  publication-title: J Clin Oncol
– volume: 7
  start-page: 11
  issue: 1
  year: 2009
  end-page: 19
  ident: CR4
  article-title: Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis
  publication-title: Clin Genitourinary Cancer
– volume: 118
  start-page: 770
  issue: 3
  year: 2012
  end-page: 776
  ident: CR98
  article-title: Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas
  publication-title: Cancer
– volume: 7
  start-page: 1073
  issue: 4
  year: 2001
  end-page: 1078
  ident: CR33
  article-title: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor
  publication-title: Clin Cancer Res
– volume: 1
  start-page: 44
  issue: 1
  year: 2011
  end-page: 53
  ident: CR57
  article-title: The BATTLE trial: personalizing therapy for lung cancer
  publication-title: Cancer Dis
– volume: 62
  start-page: 1006
  issue: 10
  year: 2009
  end-page: 1012
  ident: CR13
  article-title: Preferred Reporting Items for Systematic reviews and Meta-Analyses: the PRISMA statement
  publication-title: J Clin Epidemiol
– volume: 26
  start-page: 4714
  issue: 29
  year: 2008
  end-page: 4719
  ident: CR71
  article-title: Phase II trial of sorafenib in advanced thyroid cancer
  publication-title: J Clin Oncol
– volume: 35
  start-page: 468
  issue: 6
  year: 2012
  end-page: 476
  ident: CR38
  article-title: Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib
  publication-title: Kidney Blood Press Res
– volume: 304
  start-page: 2154
  issue: 19
  year: 2010
  end-page: 2160
  ident: CR54
  article-title: Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial
  publication-title: JAMA
– volume: 109
  start-page: 200
  issue: 2
  year: 2012
  end-page: 206
  ident: CR99
  article-title: Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment
  publication-title: BJU Int
– volume: 420
  start-page: 28
  issue: 1
  year: 1997
  end-page: 32
  ident: CR20
  article-title: Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase
  publication-title: FEBS Lett
– volume: 165
  start-page: 315
  issue: 2
  year: 2011
  end-page: 322
  ident: CR97
  article-title: Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population
  publication-title: Eur J Endocrinol
– volume: 19
  start-page: 746
  issue: 4
  year: 2008
  end-page: 751
  ident: CR67
  article-title: A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
  publication-title: Ann Oncol
– volume: 27
  start-page: 4274
  issue: 26
  year: 2009
  end-page: 4280
  ident: CR80
  article-title: Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer
  publication-title: J Clin Oncol
– volume: 115
  start-page: 428
  issue: 2
  year: 2009
  end-page: 436
  ident: CR74
  article-title: Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response
  publication-title: Cancer
– volume: 95
  start-page: 581
  issue: 5
  year: 2006
  end-page: 586
  ident: CR62
  article-title: Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
  publication-title: Br J Cancer
– volume: 28
  start-page: 1835
  issue: 11
  year: 2010
  end-page: 1842
  ident: CR43
  article-title: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer
  publication-title: J Clin Oncol
– volume: 42
  start-page: 1206
  issue: 6
  year: 2003
  ident: BFjhh201330_CR16
  publication-title: Hypertension
  doi: 10.1161/01.HYP.0000107251.49515.c2
– volume: 27
  start-page: abstr 6058
  issue: suppl
  year: 2009
  ident: BFjhh201330_CR77
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2009.27.15_suppl.6058
– volume: 116
  start-page: 5686
  issue: 24
  year: 2010
  ident: BFjhh201330_CR92
  publication-title: Cancer
  doi: 10.1002/cncr.25448
– volume: 98
  start-page: 671
  issue: 3
  year: 1996
  ident: BFjhh201330_CR32
  publication-title: J Clin Invest
  doi: 10.1172/JCI118838
– ident: BFjhh201330_CR3
– volume: 62
  start-page: 1006
  issue: 10
  year: 2009
  ident: BFjhh201330_CR13
  publication-title: J Clin Epidemiol
  doi: 10.1016/j.jclinepi.2009.06.005
– volume: 29
  start-page: 69
  issue: 1
  year: 2011
  ident: BFjhh201330_CR90
  publication-title: J clin Oncol
  doi: 10.1200/JCO.2009.26.7856
– volume: 30
  start-page: 2377
  issue: 6
  year: 2012
  ident: BFjhh201330_CR100
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-012-9795-9
– volume: 27
  start-page: 11
  issue: 1
  year: 2009
  ident: BFjhh201330_CR73
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.15.5242
– volume: 26
  start-page: abstr 10502
  issue: suppl
  year: 2008
  ident: BFjhh201330_CR70
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2008.26.15_suppl.10502
– volume: 7
  start-page: e26331
  issue: 2
  year: 2012
  ident: BFjhh201330_CR102
  publication-title: PloS One
  doi: 10.1371/journal.pone.0026331
– volume: 26
  start-page: 4714
  issue: 29
  year: 2008
  ident: BFjhh201330_CR71
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.16.3279
– ident: BFjhh201330_CR39
  doi: 10.1200/jco.2012.30.15_suppl.4503
– volume: 20
  start-page: 616
  issue: 7
  year: 2009
  ident: BFjhh201330_CR81
  publication-title: Anticancer Drugs
  doi: 10.1097/CAD.0b013e32832b2ea0
– volume: 29
  start-page: abstr 10009
  issue: suppl
  year: 2011
  ident: BFjhh201330_CR96
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2011.29.15_suppl.10009
– volume: 26
  start-page: abstr 8014
  issue: suppl
  year: 2008
  ident: BFjhh201330_CR69
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2008.26.15_suppl.8014
– volume: 30
  start-page: abstr 4546
  issue: suppl
  year: 2012
  ident: BFjhh201330_CR47
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2012.30.15_suppl.4546
– volume: 14
  start-page: 3470
  issue: 11
  year: 2008
  ident: BFjhh201330_CR25
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-5050
– volume: 19
  start-page: 746
  issue: 4
  year: 2008
  ident: BFjhh201330_CR67
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdm554
– volume: 103
  start-page: 1636
  issue: 12
  year: 2009
  ident: BFjhh201330_CR75
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2008.08327.x
– volume: 109
  start-page: 200
  issue: 2
  year: 2012
  ident: BFjhh201330_CR99
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2011.10421.x
– volume: 17
  start-page: 1190
  issue: 5
  year: 2011
  ident: BFjhh201330_CR93
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-2331
– volume: 30
  start-page: 3084
  issue: 25
  year: 2012
  ident: BFjhh201330_CR50
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.39.7646
– volume: 29
  start-page: abstr 4028
  issue: suppl
  year: 2011
  ident: BFjhh201330_CR44
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2011.29.15_suppl.4028
– volume: 117
  start-page: 37
  issue: 1
  year: 2010
  ident: BFjhh201330_CR83
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2010.01.013
– volume: 304
  start-page: 2154
  issue: 19
  year: 2010
  ident: BFjhh201330_CR54
  publication-title: JAMA
  doi: 10.1001/jama.2010.1672
– volume: 5
  start-page: e15588
  issue: 12
  year: 2010
  ident: BFjhh201330_CR91
  publication-title: PloS One
  doi: 10.1371/journal.pone.0015588
– volume: 100
  start-page: 282
  issue: 4
  year: 2008
  ident: BFjhh201330_CR30
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djm311
– volume: 118
  start-page: 770
  issue: 3
  year: 2012
  ident: BFjhh201330_CR98
  publication-title: Cancer
  doi: 10.1002/cncr.26334
– ident: BFjhh201330_CR9
– volume: 98
  start-page: 2604
  issue: 5
  year: 2001
  ident: BFjhh201330_CR36
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.041359198
– volume: 64
  start-page: 7099
  issue: 19
  year: 2004
  ident: BFjhh201330_CR1
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-1443
– volume: 27
  start-page: 4274
  issue: 26
  year: 2009
  ident: BFjhh201330_CR80
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.22.0541
– volume: 59
  start-page: 816
  issue: 6
  year: 2002
  ident: BFjhh201330_CR18
  publication-title: Urology
  doi: 10.1016/S0090-4295(02)01501-7
– volume: 47
  start-page: 2117
  issue: 14
  year: 2011
  ident: BFjhh201330_CR45
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2011.05.007
– volume: 27
  start-page: 4469
  issue: 27
  year: 2009
  ident: BFjhh201330_CR79
  publication-title: J Clin OncolJ
  doi: 10.1200/JCO.2009.22.6480
– volume: 116
  start-page: 57
  issue: 1
  year: 2010
  ident: BFjhh201330_CR53
  publication-title: Cancer
  doi: 10.1002/cncr.24685
– volume: 360
  start-page: 1903
  issue: 9349
  year: 2002
  ident: BFjhh201330_CR27
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)11911-8
– volume: 130
  start-page: 691
  issue: 4
  year: 2007
  ident: BFjhh201330_CR24
  publication-title: Cell
  doi: 10.1016/j.cell.2007.06.054
– volume: 10
  start-page: 967
  issue: 10
  year: 2009
  ident: BFjhh201330_CR6
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(09)70222-0
– volume: 12
  start-page: 503
  issue: 7
  year: 2010
  ident: BFjhh201330_CR87
  publication-title: Clin Transl Oncol
  doi: 10.1007/s12094-010-0544-2
– ident: BFjhh201330_CR15
– volume: 17
  start-page: 260
  issue: 2
  year: 2012
  ident: BFjhh201330_CR101
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2011-0237
– volume: 9
  start-page: 117
  issue: 2
  year: 2008
  ident: BFjhh201330_CR11
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(08)70003-2
– volume: 14
  start-page: 209
  issue: 1
  year: 2008
  ident: BFjhh201330_CR68
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-1355
– volume: 378
  start-page: 1931
  issue: 9807
  year: 2011
  ident: BFjhh201330_CR46
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)61613-9
– volume: 15
  start-page: 6250
  issue: 19
  year: 2009
  ident: BFjhh201330_CR23
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-0058
– volume: 9
  start-page: 86
  issue: 2
  year: 2008
  ident: BFjhh201330_CR12
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(08)70009-3
– volume: 10
  start-page: 25
  issue: 1
  year: 2009
  ident: BFjhh201330_CR42
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(08)70285-7
– volume: 28
  start-page: 1835
  issue: 11
  year: 2010
  ident: BFjhh201330_CR43
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.26.1321
– volume: 274
  start-page: H1054
  issue: 3 Pt 2
  year: 1998
  ident: BFjhh201330_CR19
  publication-title: Am J Physiol
– volume: 19
  start-page: 927
  issue: 5
  year: 2008
  ident: BFjhh201330_CR26
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdm550
– volume: 28
  start-page: 2323
  issue: 14
  year: 2010
  ident: BFjhh201330_CR85
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.25.0068
– ident: BFjhh201330_CR37
– volume: 51
  start-page: 168
  issue: 1
  year: 2007
  ident: BFjhh201330_CR17
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2006.06.026
– volume: 95
  start-page: 581
  issue: 5
  year: 2006
  ident: BFjhh201330_CR62
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6603291
– volume: 80
  start-page: 291
  issue: 2
  year: 2011
  ident: BFjhh201330_CR8
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2010.11.007
– volume: 116
  start-page: 5383
  issue: 23
  year: 2010
  ident: BFjhh201330_CR89
  publication-title: Cancer
  doi: 10.1002/cncr.25327
– volume: 1
  start-page: 44
  issue: 1
  year: 2011
  ident: BFjhh201330_CR57
  publication-title: Cancer Dis
  doi: 10.1158/2159-8274.CD-10-0010
– volume: 30
  start-page: abstr 4539
  issue: suppl
  year: 2012
  ident: BFjhh201330_CR48
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2012.30.15_suppl.4539
– volume: 24
  start-page: 2505
  issue: 16
  year: 2006
  ident: BFjhh201330_CR61
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.03.6723
– volume: 5
  start-page: 1655
  issue: 10
  year: 2010
  ident: BFjhh201330_CR88
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e3181ec18db
– volume: 29
  start-page: 2582
  issue: 18
  year: 2011
  ident: BFjhh201330_CR58
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.30.7678
– volume: 39
  start-page: 454
  issue: 5
  year: 2012
  ident: BFjhh201330_CR34
  publication-title: Clin Exp Pharmacol Physiol
  doi: 10.1111/j.1440-1681.2012.05699.x
– volume: Vol 25
  start-page: 4504
  issue: No. 18S
  year: 2007
  ident: BFjhh201330_CR63
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2007.25.18_suppl.4504
– volume: 48
  start-page: 9
  issue: 1
  year: 2009
  ident: BFjhh201330_CR10
  publication-title: Acta Oncol
  doi: 10.1080/02841860802314720
– volume: 27
  start-page: 3133
  issue: 19
  year: 2009
  ident: BFjhh201330_CR78
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.20.4495
– volume: 356
  start-page: 125
  issue: 2
  year: 2007
  ident: BFjhh201330_CR28
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa060655
– volume: 420
  start-page: 28
  issue: 1
  year: 1997
  ident: BFjhh201330_CR20
  publication-title: FEBS Lett
  doi: 10.1016/S0014-5793(97)01481-6
– volume: 27
  start-page: 6152
  issue: 36
  year: 2009
  ident: BFjhh201330_CR35
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.22.2273
– volume: 7
  start-page: 3129
  issue: 10
  year: 2008
  ident: BFjhh201330_CR2
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-08-0013
– volume: 30
  start-page: 1484
  issue: 13
  year: 2012
  ident: BFjhh201330_CR59
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.36.7771
– volume: 28
  start-page: 3330
  issue: 20
  year: 2010
  ident: BFjhh201330_CR86
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.25.6834
– volume: 23
  start-page: 508
  issue: 2
  year: 2012
  ident: BFjhh201330_CR95
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdr151
– volume: 359
  start-page: 378
  issue: 4
  year: 2008
  ident: BFjhh201330_CR41
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0708857
– volume: 27
  start-page: 1675
  issue: 10
  year: 2009
  ident: BFjhh201330_CR76
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.18.2717
– volume: 28
  start-page: 21
  issue: 1
  year: 2010
  ident: BFjhh201330_CR72
  publication-title: Urol Oncol
  doi: 10.1016/j.urolonc.2008.06.003
– volume: 28
  start-page: 1502
  issue: 9
  year: 2010
  ident: BFjhh201330_CR84
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.24.7759
– volume: 30
  start-page: abstr LBA154
  issue: suppl 4
  year: 2012
  ident: BFjhh201330_CR60
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2012.30.4_suppl.lba154
– volume: 161
  start-page: 923
  issue: 6
  year: 2009
  ident: BFjhh201330_CR82
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-09-0702
– volume: 28
  start-page: 2280
  issue: 13
  year: 2010
  ident: BFjhh201330_CR7
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.27.2757
– volume: 97
  start-page: 1480
  issue: 11
  year: 2007
  ident: BFjhh201330_CR66
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6604064
– volume: 17
  start-page: 2793
  issue: 11
  year: 1997
  ident: BFjhh201330_CR21
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.17.11.2793
– volume: 48
  start-page: 47
  issue: 1
  year: 2011
  ident: BFjhh201330_CR55
  publication-title: Indian J Cancer
  doi: 10.4103/0019-509X.75825
– volume: 68
  start-page: 9112
  issue: 22
  year: 2008
  ident: BFjhh201330_CR31
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-0851
– volume: 35
  start-page: 468
  issue: 6
  year: 2012
  ident: BFjhh201330_CR38
  publication-title: Kidney Blood Press Res
  doi: 10.1159/000338175
– volume: 104
  start-page: 1256
  issue: 8
  year: 2011
  ident: BFjhh201330_CR56
  publication-title: Br Jo Cancer
  doi: 10.1038/bjc.2011.103
– volume: 115
  start-page: 428
  issue: 2
  year: 2009
  ident: BFjhh201330_CR74
  publication-title: Cancer
  doi: 10.1002/cncr.24029
– volume: 165
  start-page: 315
  issue: 2
  year: 2011
  ident: BFjhh201330_CR97
  publication-title: Eur J Endocrinol
  doi: 10.1530/EJE-11-0129
– volume: 7
  start-page: 1073
  issue: 4
  year: 2001
  ident: BFjhh201330_CR33
  publication-title: Clin Cancer Res
– volume: 27
  start-page: 3312
  issue: 20
  year: 2009
  ident: BFjhh201330_CR40
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.19.5511
– volume: 7
  start-page: 11
  issue: 1
  year: 2009
  ident: BFjhh201330_CR4
  publication-title: Clin Genitourinary Cancer
  doi: 10.3816/CGC.2009.n.002
– volume: 26
  start-page: 2178
  issue: 13
  year: 2008
  ident: BFjhh201330_CR51
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.14.8288
– volume: 25
  start-page: 3766
  issue: 24
  year: 2007
  ident: BFjhh201330_CR64
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.10.2871
– volume: 47
  start-page: 176
  issue: 2
  year: 2008
  ident: BFjhh201330_CR5
  publication-title: Acta Oncol
  doi: 10.1080/02841860701765675
– volume: 27
  start-page: 1280
  issue: 8
  year: 2009
  ident: BFjhh201330_CR52
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.19.3342
– volume: 30
  start-page: abstr 4501
  issue: suppl
  year: 2012
  ident: BFjhh201330_CR49
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2012.30.15_suppl.4501
– volume: 24
  start-page: e48
  issue: 28
  year: 2006
  ident: BFjhh201330_CR29
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.08.4608
– volume: 108
  start-page: 1813
  issue: 11
  year: 2011
  ident: BFjhh201330_CR94
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2011.10281.x
– volume: 30
  start-page: abstr 10020
  issue: suppl
  year: 2012
  ident: BFjhh201330_CR103
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2012.30.15_suppl.10020
– ident: BFjhh201330_CR14
– volume: 107
  start-page: 1359
  issue: 10
  year: 2003
  ident: BFjhh201330_CR22
  publication-title: Circulation
  doi: 10.1161/01.CIR.0000061911.47710.8A
– volume: 37
  start-page: 755
  issue: 10
  year: 2007
  ident: BFjhh201330_CR65
  publication-title: Jpn J Clin Oncol
  doi: 10.1093/jjco/hym095
SSID ssj0014768
Score 2.2848759
SecondaryResourceType review_article
Snippet Sorafenib, a multi-kinase inhibitor, has been reported to be associated with hypertension (HTN). However, the risk of severe HTN with sorafenib treatment has...
SourceID proquest
gale
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 601
SubjectTerms 692/699/67
692/699/75/243
692/700/565/1436
692/700/565/2194
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Blood Pressure - drug effects
Cancer
Cancer patients
Chemotherapy
Chi-Square Distribution
Clinical trials
Drug Administration Schedule
Enzyme inhibitors
Epidemiology
Health Administration
Health aspects
Humans
Hypertension
Hypertension - chemically induced
Hypertension - diagnosis
Hypertension - epidemiology
Hypertension - physiopathology
Immunotherapy
Incidence
Inhibitor drugs
Kidney cancer
Medicine & Public Health
Meta-analysis
Molecular Targeted Therapy - adverse effects
Neoplasms - drug therapy
Neoplasms - enzymology
Niacinamide - administration & dosage
Niacinamide - adverse effects
Niacinamide - analogs & derivatives
Odds Ratio
original-article
Patients
Phenylurea Compounds - administration & dosage
Phenylurea Compounds - adverse effects
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Public Health
Renal cell carcinoma
Risk Factors
Severity of Illness Index
Sorafenib
Targeted cancer therapy
Terminology
Time Factors
Title Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
URI https://link.springer.com/article/10.1038/jhh.2013.30
https://www.ncbi.nlm.nih.gov/pubmed/23636006
https://www.proquest.com/docview/1431395577
https://www.proquest.com/docview/2640658918
https://www.proquest.com/docview/1432074583
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1da9wwzGwtjL2M7rO3tZ0HHYNB1iR2EqcvoxstZdAyygr3FmTHpre1ye1y9_8rOb70rit7yYtEnEiWJVlfjO0DmuAOIEYRNyaSkOcRyNxExkmVu1RqY8hRPDvPTy_lj3E2DhduXUirXJ6J_qCuW0N35AeouElblon6Ov0b0dQoiq6GERqP2Sa1LqOUrmI8OFyJLHwpHFoRcYR-Rhzq82KhDn5fUSQiEV8o_XlFI90_l1cU071IqVdAJ1vsWbAc-VHP6ufskW1esCdnITb-kjUXk-4Pbx2_Qtdy5hPT24ZPGm6IsTMeOqh23OeW25rTFSzvcAs420z0IYeGL6a1B931d-Z9bQsCa35j5xBB6GLyil2eHP_6fhqFaQqRkSqeR0mKro4wBhmgFMSmcEKABulcnaRaJtLVqJlKSEGilQAZehKgpVXILZEBPl6zjaZt7DbjGqDONNoiaWlolrqWqTPaitLgyS9AjNjnJUUrE1qN08SL68qHvIWqkPwVkb8S8YjtD8jTvsPGw2jviTVVXx46yGV1JCRaJKUq8xH75DFIMnE1A6HAAL-ZelytYe6sYaJEmXXwkv1VkOgOXSSB0CwrigfBd9tzxD4MYHoxJbE1tl34V6RosWUKCfSm31XDH6eCGrfFuPbH5TZbWftfcrz9_0e8Y08Jsc863GEb89nC7qL1NNd7XkT22Oa34_OfF7eDfhoQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQwcFS2EnBBvFko1EitkJDSJraTdZAQKtBqS7srVLVSb8F2bHVbSJZ9CPFTfCPjxEl3S8Wtl1zGsZ3xeB6ZF8CGRBXcShniFdc64DJJAskTHWjLRWIpV1o7Q3EwTPon_MtpfLoCf5pcGBdW2fDEilHnpXb_yLdRcDtpmUbiw_hn4LpGOe9q00KjJosD8_sXmmzT9_uf8Xw3Kd3bPf7UD3xXgUBzEc6CiKLKz7TGjQghQ92zjEklubV5RBWPuM2RQ6eSSo7SUsaoUUvFjcBds1jiA-e9BaucoSnTgdWPu8OvR63fgveq5DvUW8IALZvQZwSGTGyfnznfR8S2XMD1ggy8KgkWROEV32wl8vbuwz2vq5KdmrgewIopHsLtgffGP4LiaDS9IKUlZ2jMTqpQ-LIgo4JoR0oT4mu2TkkVzW5y4n76kikSnTXFSL0jsiDzcV6BLitKkzqbBoE5-WFmMpC-bspjOLkRTD-BTlEW5hkQJWUeK9R-aKpd93bFqdXKsFSjrGGSdeFtg9FM--LmrsfG96xysjORIfozh_6MhV3YaAeP65oe1w9bd0eT1QmpLSfIdhhHHSgVadKFN9UIxwtwNS19SgPu2VXVWhq5tjQS77BeBjfHn3keMkWjjCE0jnu9a8GXF6ILr1uwm9iFzRWmnFdTUNQRY4EIelpTVfvFlLlScSGuvdmQ2cLa_6Lj-f83sQ53-seDw-xwf3jwAu66l-qYxzXozCZz8xJ1t5l65S8MgW83fUf_AubFV3k
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1db9Mw0BpDmnhBfFMYzEibkJBCE9tJHCSEJka1MTYhxKS-BduJtbKRlKYV4q_x67hznKwdE297ycs5tnO-z9yHCdlWYIJbpUJgcWMCoZIkUCIxgbFCJpYJbQw6ikfHyf6J-DiOx2vkT1cLg2mVnUx0grqoDf4jH4LiRm2ZRXJofVrE573Ru-nPAG-Qwkhrd51GSyKH5e9f4L41bw_24Kx3GBt9-Pp-P_A3DARGyHAeRAzMf24MbEpKFZrUcq60EtYWEdMiErYAaZ0ppgRoThWDda20KCV8AY8VPGDeG-RmyuMIeSwd985eJFJXhgcWTBiAjxP62sCQy-H3U4yCRPw1pl4vacPLOmFJKV6K0jrlN7pDbnurle62ZHaXrJXVPbJx5OPy90n1ZdKc0drSU3BrZy4pvq7opKIGiWpGfffWhrq89rKg-PuXNkB-tqwm-g1VFV1MCwe66C1N27oaABb0RzlXgfIdVB6Qk2vB80OyXtVV-ZhQrVQRa7CDWGbwHnctmDW65JkBrcMVH5BXHUZz49uc420b57kLt3OZA_pzRH_OwwHZ7gdP2-4eVw_bwqPJ29LUXibku1yANZTJLBmQl24ESgVYzShf3AB7xv5aKyM3V0YCN5tVcHf8uZcmDbhnHKBxnKZXgi9YY0Be9GCcGBPoqrJeuCkYWIuxBAQ9aqmq_2LGsWlcCGvvdGS2tPa_6Hjy_01skQ3gzPzTwfHhU3IL32mTHzfJ-ny2KJ-BETfXzx23UPLtutnzLwyYWkk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+of+hypertension+in+cancer+patients+treated+with+sorafenib%3A+an+updated+systematic+review+and+meta-analysis&rft.jtitle=Journal+of+human+hypertension&rft.au=Funakoshi%2C+T&rft.au=Latif%2C+A&rft.au=Galsky%2C+M+D&rft.date=2013-10-01&rft.pub=Nature+Publishing+Group+UK&rft.issn=0950-9240&rft.eissn=1476-5527&rft.volume=27&rft.issue=10&rft.spage=601&rft.epage=611&rft_id=info:doi/10.1038%2Fjhh.2013.30&rft.externalDocID=10_1038_jhh_2013_30
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-9240&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-9240&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-9240&client=summon